A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT04777201 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1036

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Faricimab
OTHER: Sham Procedure
DRUG: Anti-VEGF Therapy

Sponsor

Hoffmann-La Roche